FDA approves Rituxan for lymphoma maintenance

fda-logo.jpg

The US Food and Drug Administration has approved the use of the anti-CD20 monoclonal antibody Rituxan (rituximab) in patients with advanced stage follicular lymphoma who have previously had a response to first-line or induction therapy that included Rituxan and chemotherapy.

Approval was given based on the results from the so-called PRIMA (Primary Rituxan and Maintenance) study.

LymphomaInfo Social